Thank you again for question.
Madam Chair, I certainly would agree that the Patented Medicine Prices Review Board is a very critical and important institution. I would characterize the reduction in two ways.
One is that there are some administrative savings that they have found and that I think they feel they can manage with no impact, certainly, on their services.
They also were able to reduce funding they had set aside for hearings. Hearings are quite costly in their case, and again, there can be a number of years in which they hold a number of hearings. Their budget is increased to consolidate that. They've found that in recent years they simply weren't spending this money because they didn't need it. The hearings weren't required. They have indicated to us that they feel there will be no impact on their ability to fulfill their functions, because at current levels they were not needing those funds.
Thank you.